Conformational selection of inhibitors and substrates by proteolytic enzymes: Implications for drug design and polypeptide processing

Journal of Medicinal Chemistry

Volumn 43, Issue 7, 2000, Pages 1271-1281

  Fairlie, David P ^a   Tyndall, Joel D A ^a   Reid, Robert C ^a   Wong, Allan K ^a   Abbenante, Giovanni ^a   Scanlon, Martin J ^a   March, Darren R ^a   Bergman, Douglas A ^a   Chai, Christina L L ^b   Burkett, Brendan A ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; COMPUTER ANALYSIS; DRUG CONFORMATION; DRUG DESIGN; ENZYME CONFORMATION; ENZYME INHIBITOR COMPLEX; ENZYME SUBSTRATE; MOLECULAR RECOGNITION; NUCLEAR MAGNETIC RESONANCE; PROTEIN PROCESSING;

AMINO ACID SEQUENCE; BINDING SITES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCULAR DICHROISM; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENDOPEPTIDASES; HIV PROTEASE; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; SUBSTRATE SPECIFICITY;

EID: 0034611591     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990315t     Document Type: Article

References (73)

1. (a) Leung, D.; Abbenante, G.; Fairlie, D. P. Protease Inhibitors: Current Status and Future Prospects. J. Med. Chem. 2000, 43, 305-41.
2. (b) Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359-472.
3. (c) Craik, C. S.; Debouck, C. Proteases as Therapeutic Targets. In Perspectives in Drug Discovery and Design; McKerrow, J. H., James, M. N. G., Eds.; ESCOM: Leiden, 1995; Vol. 2, pp 1-125.
4. (d) Van Noorden, J. F. IBC's 2nd International Conference on Protease Inhibitors: Novel Therapeutic Applications and Development, Washington D.C., Feb 24-26, 1997; Acta Histochem. 1997, 99, 249-55.
5. (d) Van Noorden, J. F. IBC's 2nd International Conference on Protease Inhibitors: Novel Therapeutic Applications and Development, Washington D.C., Feb 24-26, 1997; Acta Histochem. 1997, 99, 249-55.
6. (a) Beckett, R. P.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Whittaker, M. Recent Advances in matrix metalloprotease inhibitor research. DDT 1996, 1, 16.
7. (b) Johnson, L. L.; Dyer, R.; Hupe, D. J. Matrix metalloproteinases. Curr. Opin. Chem. Biol. 1998, 2, 466-71.
8. (c) Yan, S.; Sameni, M.; Sloane, B. F. Cathepsin B and human tumor progression. J. Biol Chem. 1998, 379, 113-23.
9. (a) Becker, M. M.; Harrop, S. A.; Dalton, J. P.; Kalinna, B. H.; McManus, D. P.; Brindley, P. J. Cloning and characterization of the Schistosoma japonicum aspartic proteinase involved in hemoglobin degradation. J. Biol. Chem. 1995, 270, 24496-501; erratum: J. Biol. Chem. 1997, 272, 17246.
10. (b) Brindley, P. J.; Kalinna, B. H.; Dalton, J. P.; Day, S. R.; Wong, J. W.; Smythe, M. L.; McManus, D. P. Proteolytic degradation of host hemoglobin by schistosomes. Mol. Biochem. Parasitol. 1997, 89, 1-9.
11. (a) Silva, A. M.; Lee, A. Y.; Gulnik, S. V.; Maier, P.; Collins, J.; Bhat, T. N.; Collins, P. J.; Cachau, R. E.; Luker, K. E.; Gluzman, I. Y.; Francis, S. E.; Oksman, A.; Goldberg, D. E.; Erickson, J. W. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 10034-9.
12. (b) Li, Z.; Chen, X.; Davidson, E.; Zwang, O.; Mendis, C.; Ring, C. S.; Roush, W. R.; Fegley, G.; Li, R.; Rosenthal, P. J.; et al. Anti-malarial drug development using models of enzyme structure. Chem. Biol. 1994, 1, 31-7.
13. (a) Abad-Zapatero, C.; Goldman, R. W.; Muchmore, S. W.; Hutchins, C.; Stewart, K.; Navaza, J.; Payne, C. D.; Ray, T. L. Structure of a secreted aspartic protease from C. Albicans complexed with a potent inhibitor: implications for the design of antifungal agents. Protein Sci. 1996, 5, 640-52.
14. (b) Abad-Zapatero, C.; Goldman, R.; Muchmore, S. W.; Hutchins, C.; Oie, T.; Stewart, K.; Cutfield, S. M.; Cutfield, J. F.; Foundling, S. I.; Ray, T. L. Structure of secreted aspartic proteinases from Candida. Implications for the design of antifungal agents. Adv. Exp. Med. Biol. 1998, 436, 297-313.
15. (a) Wlodawer, A.; Erickson, J. W. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 1993 62, 543-85.
16. (b) Darke, P. L.; Huff, J. R. HIV protease as an inhibitor target for the treatment of AIDS. Adv. Pharmacol. 1994, 25, 399-454.
17. (c) West, M. L.; Fairlie, D. P. Targeting HIV-1 protease: a test of drug-design methodologies. Trends Pharmacol. Sci. 1995, 16, 67-75.
18. (d) Kempf, D. J.; Sham, H. L. HIV protease inhibitors. Curr. Pharm. Des. 1996, 2, 225-46.
19. (e) March, D. R.; Fairlie, D. P. Designing new antiviral drugs for AIDS: HIV-1 Protease and its inhibitors; R. G. Landes Co.: Austin, TX, 1996.
20. (a) Kim, J. L.; Morgenstern, K. A.; Lin, C.; Fox, T.; Dwyer, M. D.; Landro, J. A.; Chambers, S. P.; Markland, W.; Lepre, C. A.; O'Malley, E. T.; Harbeson, S. L.; Rice, C. M.; Murcko, M. A.; Caron, P. R.; Thomson, J. A. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996, 87, 343-55; erratum: Cell 1997, 8, 159.
21. (b) Love, R. A.; Parge, H. E.; Wickersham, J. A.; Hostomsky, Z.; Habuka, N.; Moomaw, E. W.; Adachi, T.; Hostomska, Z. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996, 87, 331-42.
22. (a) Gibson, W.; Hall, M. R. Assemblin, an essential herpesvirus proteinase. Drug Des. Discov. 1997, 15, 39-47.
23. (b) Shieh, H. S.; Kurumbail, R. G.; Stevens, A. M.; Stegeman, R. A.; Sturman, E. J.; Pak, J. Y.; Wittwer, A. J.; Palmier, M. O.; Wiegand, R. C.; Holwerda, B. C.; Stallings, W. C. Three-dimensional structure of human cytomegalovirus protease. Nature 1996, 383, 279-82; erratum: Nature 1996, 384, 288.
24. Boycott, R.; Klenk, H. D.; Ohuchi, M. Cell tropism of influenza virus mediated by hemagglutinin activation at the stage of virus entry. Virology 1994, 203, 313-9.
25. (a) Bernstein, P. R.; Edwards, P. D.; Williams, J. C. Inhibitors of human leukocyte elastase. Prog. Med. Chem. 1994, 31, 59-120.
26. (b) Hugli, T. E. Protease inhibitors: novel therapeutic application and development. Trends Biotechnol. 1996, 14, 409-12.
27. (c) Fath, M. A.; Wu, X.; Hileman, R. E.; Linhardt, R. J.; Kashem, M. A.; Nelson, R. M.; Wright, C. D.; Abraham, W. M. Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma. J. Biol. Chem. 1998, 273, 13563-9.
28. (d) Tanaka, R. D.; Clark, J. M.; Warne, R. L.; Abraham, W. M.; Moore, W. R. Mast cell tryptase: a new target for therapeutic intervention in asthma. Int. Arch Allergy Immunol. 1995, 107, 408-9.
29. Stubbs, M. T.; Bode, W. A player of many parts: the spotlight falls on thrombin's structure. Thromb Res. 1993, 69, 1-58.
30. (a) Selkoe, D. J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997, 275, 630-1. Vassar, R.; Bennett, B. D.; Babu-Khan, S.; Khan, S.; et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286, 735-741.
31. (a) Selkoe, D. J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997, 275, 630-1. Vassar, R.; Bennett, B. D.; Babu-Khan, S.; Khan, S.; et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286, 735-741.
32. Seife, C. Blunting nature's Swiss army knife. Science 1997, 277, 1602-3.
33. (a) See references to all PDB-filed structures in Table 1.
34. (b) Rich, D. H. Peptidase Inhibitors. In Comprehensive Medicinal Chemistry; Samuels, P. J., Ed.; Pergamon Press: Oxford, 1990; Vol. 2, pp 391-441 and references therein.
35. (a) James, M. N. G.; Sielecki, A. R. Aspartic proteases and their Catalytic Pathway inhibitors. In Biological Macromolecules and Assemblies: Active sites of enzymes; Jurnak, F. A., McPherson, A., Eds.; John Wiley & Sons: New York, 1987; p 413.
36. (b) Bailey, D.; Cooper, J. B. A structural comparison of 21 inhibitor complexes of the aspartic proteinase from Endothia parasitica. Protein Sci. 1994, 3, 2129-43.
37. Powers, J. C.; Harper, J. W. Inhibitors of serine proteases. In Protease Inhibitors; Barret, A. J. S., Salverson, G., Eds.; Elsevier: Amsterdam, 1986; pp 55-152.
38. Powers, J. C.; Harper, J. W. Inhibitors of metalloproteases. In Protease Inhibitors; Barret, A. J. S., Salverson, G., Eds.; Elsevier: Amsterdam, 1986; pp 219-98.
39. (a) Hans-Hartwig, O.; Schirmeister, T. Cysteine proteases and their inhibitors. Chem. Rev. 1997, 97, 133-71.
40. (b) Rasnick, D. Small synthetic inhibitors of cysteine protease. In Perspectives in Drug Discovery and Design; McKerrow, J. H., James, M. N. G., Eds.; ESCOM: Leiden, 1996; pp 47-63.
41. Dauter, Z.; Betzel, C.; Genov, N.; Pipon, N.; Wilson, K. S. Complex between the subtilisin from a mesophilic bacterium and the leech inhibitor eglin-C. Acta Crystallogr. B 1991, 47, 707-30.
42. (a) Fairlie, D. P.; Abbenante, G.; March. D. Macrocyclic Peptidomimetics: Forcing Peptides into Bioactive Conformations. Curr. Med. Chem. 1995, 2, 672-705.
43. (b) Fairlie, D. P.; West, M. L.; Wong, A. K. Towards protein surface mimetics. Curr. Med. Chem. 1998, 5, 29-62.
44. (c) Reid, R. C.; Fairlie, D. P. Mimicking extended conformations of protease substrates: designing cyclic peptidomimetics to inhibit HIV-1 Protease. Advances in Amino Acid Mimetics and peptidomimetics; JAI Press Inc.: Greenwich, CT, 1997; pp 77-107.
45. (a) Smith III, A. B.; Keenan, T. P.; Holcomb, R. C.; Sprengeler, P. A.; Guzman, M. C.; Wood, J. L.; Carol, P. J.; Hirschman, R. Design, synthesis and crystal structure of a pyrrolinone-based peptidomimetic possessing the conformation of a β-strand: Potential application to the design of novel inhibitors of proteolytic enzymes. J. Am. Chem. Soc. 1992, 114, 10672-74.
46. (b) Smith III, A. B.; Hirschmann, R.; Pasternack, A.; Akaishi, R.; Guzman, M. C.; Jones, D. R.; Keenan, T. P.; Sprengeler, P. A.; Darke, P. L.; Emini, E. A.; Holloway, M. K.; Schleif, W. A. Design and synthesis of peptidomimetic inhibitors of HIV-1 proteases and renin. Evidence for improved transport. J. Med. Chem. 1994, 37, 215-8.
47. (c) Szewczuk, Z.; Rebholz, K. L.; Rich, D. H. Synthesis and biological activity of new conformationally restricted analogues of pepstatin. Int. J. Pept. Protein Res. 1992, 40, 233-42.
48. (a) Abbenante, G.; March, D.; Bergman, D.; Hunt, P. A.; Garnham, B.; Dancer, R. J.; Martin, J. L.; Fairlie, D. P. Regioselective Structural and Functional Mimicry Of Peptides: Design Of Hydrolytically Stable Cyclic Peptidomimetic Inhibitors Of Hiv 1 Protease. J. Am. Chem. Soc. 1995, 117, 10220-6.
49. (b) March, D.; Abbenante, G.; Bergman, D.; Brinkworth, R. I.; Wickramasinghe, W.; Begun, J.; Martin, J. L.; Fairlie, D. P. Substrate Based Cyclic Peptidomimetics Of Phe Ile Val That Inhibit Hiv 1 Protease Using a Novel Enzyme Binding Mode. J. Am. Chem. Soc. 1996, 118, 3375-9.
50. (c) Reid, R. C.; March, D. R.; Dooley, M. J.; Bergman, D. A.; Abbenante, G.; Fairlie, D. P. A novel bicyclic enzyme inhibitor as a consensus peptidomimetic for the receptor-bound conformations of 12 peptidic inhibitors of HIV-1 protease. J. Am. Chem. Soc. 1996, 118, 8511-7.
51. Martin, J. L.; Begun, J.; Schindeler, A.; Wickramasinghe, W. A.; Alewood, D.; Alewood, P. F.; Bergman, D. A.; Brinkworth, R. I.; Abbenante, G.; March, D.; Reid, R. C.; Hunt, P. A.; Fairlie, D. P. Molecular Recognition of Macrocyclic Peptidomimetic inhibitors by HIV-1 Protease. Biochemistry 1999, 38, 7978-88.
52. Abbenante, G.; Bergman, D. A.; March, D. R.; Reid, R. C.; Hunt, P. A.; James, I. W.; Dancer, R. J.; Garnham, B.; Stoermer, M. L.; Fairlie, D. P. Structure-activity relationships for macrocyclic peptidomimetic inhibitors of HFV-1 protease. Bioorg. Med. Chem. Lett. 1996, 6, 2531-6.
53. Suguna, K.; Padlan, E. A.; Bott, R.; Boger, J.; Parris, K. D.; Davies, D. R. Structures of complexes of rhizopuspepsin with pepstatin and other statine-containing inhibitors. Proteins 1992, 13, 195-205.
54. Lee, A. Y.; Smitka, T. A.; Bonjouklian, R.; Clardy, J. Atomic structure of the trypsin-a90720a complex: a unified approach to structure and function. Chem. Biol. 1994, 1, 113.
55. Lee, A. Y.; Hagihara, M.; Karmacharya, R.; W.albers, M. W.; Schreiber, S. L.; Clardy, J. Atomic structure of the Trypsin-Cyclotheonamide a complex: lessons for the design of serine protease inhibitors. J. Am. Chem. Soc. 1993, 115, 12619.
56. Browner, M. F.; Smith, W. W.; Castelhano, A. L. Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry 1995, 34, 6602-10.
57. Khan, A. R.; Parrish, J. C.; Fraser, M. E.; Smith, W. W.; Bartlett, P. A.; James, M. N. Lowering the entropie barrier for binding conformationally flexible inhibitors to enzymes. Biochemistry 1998, 37, 16839-45.
58. Ding, J. H.; Fraser, M. E.; Meyer, J. H.; Bartlett, P. A.; James, M. N. G. Macrocyclic inhibitors of penicillopepsin. 2. X-ray crystallographic analyses of penicillopepsin complexed with a P3-P1 macrocyclic peptidyl inhibitor and with its two acyclic analogues. J. Am. Chem. Soc. 1998, 120, 4610-21.
59. (a) Kabsch, W.; Sander, C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983, 22, 2577-637.
60. (b) Richardson, J. S. The anatomy and taxonomy of protein structure. Adv. Protein Chem. 1981, 34, 167-339.
61. (a) Ksander, G. M.; De Jesus, R.; Yuan, A.; Ghai, R. D.; McMartin, C.; Bohacek, R. Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors. J. Med. Chem. 1997, 40, 506-14.
62. (b) Janetka, J. W.; Raman, P.; Satyshur, K.; Flentka, G.; Rich, D. H. Novel cyclic biphenyl ether β-strand mimetics and HIVProtease Inhibitors. J. Am. Chem. Soc. 1997, 119, 441-2.
63. (c) Xue, C.-B.; He, X.; Roderick, J.; DeGrado, W. F.; Cherney, R. J.; Hardman, K. D.; Nelson, D. J.; Copeland, R. A.; Jaffe, B. D.; Decicco, C. P. Design and sunthesis of cyclic inhibitors of matrix metalloproteinases and TNF-α production. J. Med. Chem. 1998, 41, 1745-8.
64. (d) Cherney, R. J.; Wang, L.; Meyer, D. T.; Xue, C.-B.; Wasserman, R.; Hardman, K. D.; Welch, P. K.; Covington, M. B.; Copeland, R. A.; Arner, E. C.; DeGrado, W. F.; Decicco, C. P. Macrocyclic amino carboxylates as selective MMP-8 inhibitors. J. Med. Chem. 1998, 41, 1749-51.
65. Ptitsyn, O. B.; Finkelstein, A. V. Theory of protein secondary structure and algorithm of its prediction. Biopolymers 1983, 22, 15-25.
66. (a) Poorman, R. A.; Tomasselli, A. G.; Heinrikson, R. L.; Kezdy, F. J. A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate database. J. Biol. Chem. 1991, 266, 14554-61.
67. (b) Tomasseli, A. G.; Heinrikson, R. L. Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates. Methods Enzymol. 1994, 241, 279-301.
68. (a) Burgen, A. S. V.; Roberts, G. C. K.; Feeney, J. Binding of flexible molecules to macromolecules. Nature 1975, 253, 753-5.
69. (b) Jencks, W. P. Catal. Chem. Enzymol. 1987, 717-9.
70. Bergman, D. A.; Alewood, D.; Alewood, P. F.; Andrews, J. L.; Brinkworth, R. I.; Englebretsen, D. R.; K. S. B. H. Kinetic-properties of HIV-1 protease produced by total chemical synthesis with cysteine residues replaced by isosteric 1-alpha-amino-N-butyric acid. Lett. Pept. Sci. 1995, 2, 99-107.
71. Toth, M. V.; Marshall, G. R. A simple, continuous fluorometric assay for HIV protease. Int. J. Pept. Protein Res. 1990, 36, 544-50.
72. Chen, Y. H.; Yang, J. T.; Chau, K. H. Determination of the helix and beta form of proteins in aqueous solution by circular dichroism. Biochemistry 1974, 13, 3350-9.
73. Scanlon, M. J.; Fairlie, D. P.; Craik, D. J.; Englebretsen, D. R.; West, M. L. NMR solution structure of the RNA-binding peptide from human immunodeficiency virus (type 1) Rev. Biochemistry 1995, 34, 8242-9.